Home / Pharmaceutical company intelligence
Citi pharma ltd logo
Pharmaceutical company intelligence

Citi pharma products and prices in Pakistan

Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.

Follow price changes 🔒 Company report (Pharma Pro)

Public listed pharmaceutical company · Lahore · Pakistan

Pakistan Stock Exchange-listed pharmaceutical company with API, formulation, nutraceutical and biotechnology-oriented manufacturing operations.

Citi pharma products in Pakistan

Citi pharma ltd has 54 medicine presentations registered in Pakistan under 23 brands, covering 22 generic medicines. Most of its products are in Anti-infectives, Pain & musculoskeletal and Cardiovascular. Its brands with the most registered strengths and packs are Triaxonecit (Ceftriaxone), Cefask (Cefixime), Flucogals (Fluconazole) and Askprol (Paracetamol). 54 products have an official DRAP price on MedInfoBase. See all 23 brands A to Z

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation11 Nov 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check9 Aug 2026Latest source-check date across this published portfolio
Latest effective price date27 Jul 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Citi Pharma Limited
Company type
Public listed pharmaceutical company
Address
588-Q Block, M.A. Johar Town, Lahore, Punjab, Pakistan
Phone
+92 49 3516587
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Semi Basic Manufacture 000429 Citi Pharma (Pvt) Ltd. · Punjab
Formulation 000512 Citi Pharma (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000512 55 linked products · source seen 11 Nov 2026 View source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx65public portfolio records represented
REG54unique registrations represented
IDX54indexed MedInfoBase presentations
SRC8additional source-observed presentations
R+3registry-only registrations
VER13registry-verified exact registrations
PKR54current validated price records
G22generic molecules in indexed catalogue
DF4dosage-form groups
TA8therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage83%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage100%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixCiti pharma ltdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/citi-pharma-ltdGenerated 11 Nov 2026Anti-infectives29 · 54%Pain & musculoskeletal8 · 15%Cardiovascular7 · 13%Gastrointestinal & hepatology4 · 7%Hematology & thrombosis3 · 6%Respiratory & allergy1 · 2%Vitamins, minerals & nutrition1 · 2%Other therapeutic areas1 · 2%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioCiti pharma ltdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/citi-pharma-ltdGenerated 11 Nov 202654presentationsTablet29 · 54%Injection10 · 19%Capsule9 · 17%Suspension6 · 11%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionCiti pharma ltdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/citi-pharma-ltdGenerated 11 Nov 202654comparable productsBelow peer median44 · 81%Near peer median8 · 15%Above peer median2 · 4%Company median price position-18.8%Lowest-price equivalents11Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsCiti pharma ltdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/citi-pharma-ltdGenerated 11 Nov 2026Nabiqasim Industries (Pvt) Ltd.,19 shared86% overlapMega Pharmaceuticals limited19 shared86% overlapBosch Pharmaceuticals (Pvt) Ltd.18 shared82% overlapZafa Pharmaceutical Laboratories (P…18 shared82% overlapBio-Labs(Pvt) Ltd17 shared77% overlapBarrett Hodgson Pakistan (Pvt.) Ltd17 shared77% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Formulation footprint

Dosage forms

Tablet29 products
Injection10 products
Capsule9 products
Suspension6 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
🔒
MedInfoBase Pharma Pro

See where Citi pharma ltd is priced against the market

54 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.

Below / near / above medianCompany price positionProduct examplesExcel, PDF & PowerPoint
Unlock with Pharma Pro
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock

Regulatory & price activity

Observed database signals

Indexed registration numbers48Distinct registrations among indexed, published, presentation-validated products only
Verified price observations54
Products with a verified price54
Products with multiple price observations0
Source records with multiple versions54
Latest portfolio source check9 Aug 2026
Latest effective price date27 Jul 2026
Latest source observation11 Nov 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

54 unique registration(s) · 54 indexed presentation(s) · 8 additional source-observed presentation(s) · 3 registry-only registration(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
*Askprin Acetylsalicylic acid (Aspirin) 75 mg Tablet 3 x 10's 030714 PKR 33.50 PKR 1.12/tablet 🔒 Pharma Pro
*Askprin Acetylsalicylic acid (Aspirin) 150 mg Tablet 3 x 10's 030715 PKR 52.65 PKR 1.76/tablet 🔒 Pharma Pro
Asknid Metronidazole 200 mg Tablet 200's 111666 PKR 295.30 PKR 1.48/tablet 🔒 Pharma Pro
Asknid Metronidazole 400 mg Tablet 200's 111667 PKR 442.95 PKR 2.21/tablet 🔒 Pharma Pro
Askprol Paracetamol 120 mg/5 mL Suspension 60ml 030725 PKR 66.01 PKR 1.10/mL 🔒 Pharma Pro
Askprol Paracetamol 120 mg/5 mL Suspension 120ml 030725 PKR 129.38 PKR 1.08/mL 🔒 Pharma Pro
Askprol Paracetamol 500 mg Tablet 20 x 10's 030726 PKR 762.93 PKR 3.81/tablet 🔒 Pharma Pro
Askprol 500 mg TabletRegistry verified Paracetamol — — — 011134-EXOfficial source ↗ No indexed price — —
Askprol XT 325 / 37.5 mg TabletRegistry verified Paracetamol, Tramadol — — — 132303Official source ↗ No indexed price — —
Avazin Cetirizine 10 mg Tablet 1 x 10's 030713 PKR 47.86 PKR 4.79/tablet 🔒 Pharma Pro
Cefask Cefixime 400 mg Capsule 1 x 5's 035202 PKR 526.25 PKR 105.25/capsule 🔒 Pharma Pro
Cefask Cefixime 100 mg/5 mL Suspension 60ml 035203 PKR 504.92 PKR 8.42/mL 🔒 Pharma Pro
Cefask Cefixime 100 mg/5 mL Suspension 30ml 035203 PKR 293.68 PKR 9.79/mL 🔒 Pharma Pro
Cefask Cefixime 200 mg Capsule 5's 121565 PKR 378.59 PKR 75.72/capsule 🔒 Pharma Pro
Cefask Cefixime 200 mg/5 mL Suspension 30ml 121566 PKR 349.47 PKR 11.65/mL 🔒 Pharma Pro
Citi Chew Ascorbic acid 500 mg Chewable tablet 40's 107233 PKR 39.61 PKR 0.99/tablet 🔒 Pharma Pro
Citiquin Hydroxychloroquine 200 mg Tablet 50's 107232 PKR 594.11 PKR 11.88/tablet 🔒 Pharma Pro
Citiquin Hydroxychloroquine 200 mg Tablet 30's 107232 PKR 356.47 PKR 11.88/tablet 🔒 Pharma Pro
Clopeg Clopidogrel 75 mg Tablet 1 x 10's 034991 PKR 223.35 PKR 22.34/tablet 🔒 Pharma Pro
Duetec Ranitidine 150 mg Tablet 1 x 10's 030729 PKR 98.40 PKR 9.84/tablet 🔒 Pharma Pro
Duetec Ranitidine 300 mg Tablet 1 x 10's 030730 PKR 178.63 PKR 17.86/tablet 🔒 Pharma Pro
Escitram Escitalopram 10 mg Tablet 10's 113233 PKR 330.06 PKR 33.01/tablet 🔒 Pharma Pro
Floxcip Ciprofloxacin 250 mg Tablet 1 x 10's 030720 PKR 224.35 PKR 22.44/tablet 🔒 Pharma Pro
Floxcip Ciprofloxacin 500 mg Tablet 1 x 10's 030721 PKR 448.70 PKR 44.87/tablet 🔒 Pharma Pro
FlucogalsSource observed Fluconazole 2000 mg Capsule 4's 111662Official source ↗ No indexed price — —
Flucogals Fluconazole 50 mg Capsule 7's 111663 PKR 594.11 PKR 84.87/capsule 🔒 Pharma Pro
Flucogals Fluconazole 150 mg Capsule 4's 111665 PKR 475.29 PKR 118.82/capsule 🔒 Pharma Pro
Flucogals Fluconazole 150 mg Capsule 1's 111665 PKR 118.82 PKR 118.82/capsule 🔒 Pharma Pro
Flucogals Fluconazole 150 mg Capsule 2's 111665 PKR 237.65 PKR 118.83/capsule 🔒 Pharma Pro
Flucogals Dry Fluconazole 50 mg/5 mL Dry suspension 35ml 111664 PKR 277.25 PKR 7.92/mL 🔒 Pharma Pro
Hi-Dol Duo Tablet 500mg/200mgRegistry verified Ibuorofen, Paracetamol — — — 124954Official source ↗ No indexed price — —
KalosSource observed Ibuprofen 120 mg/5 mL Suspension 120ml 113234Official source ↗ No indexed price — —
KalosSource observed Ibuprofen 120 mg/5 mL Suspension 150ml 113234Official source ↗ No indexed price — —
KalosSource observed Ibuprofen 120 mg/5 mL Suspension 90ml 113234Official source ↗ No indexed price — —
Kalos Ibuprofen 200 mg Tablet 100's 115526 PKR 394.32 PKR 3.94/tablet 🔒 Pharma Pro
Kalos Ibuprofen 600 mg Tablet 36's 115527 PKR 183.07 PKR 5.09/tablet 🔒 Pharma Pro
Kalos Ibuprofen 400 mg Tablet 100's 117830 PKR 357.86 PKR 3.58/tablet 🔒 Pharma Pro
Kalos 120mg/5ml suspension Each 5ml contains:- Ibuprofen……………100mg(USP Specification)Source observed — — — 120ml 113234Official source ↗ No indexed price — —
Kalos 120mg/5ml suspension Each 5ml contains:- Ibuprofen……………100mg(USP Specification)Source observed — — — 150ml 113234Official source ↗ No indexed price — —
Lenon Levofloxacin 250 mg Tablet 1 x 10's 034992 PKR 431.45 PKR 43.15/tablet 🔒 Pharma Pro
Lenon Levofloxacin 500 mg Tablet 1 x 10's 034993 PKR 717.92 PKR 71.79/tablet 🔒 Pharma Pro
Lonirupol Allopurinol 100 mg Tablet 50's 111979 PKR 88.59 PKR 1.77/tablet 🔒 Pharma Pro
Lonirupol Allopurinol 300 mg Tablet 20's 111980 PKR 92.42 PKR 4.62/tablet 🔒 Pharma Pro
Lopec Losartan 50 mg Tablet 2 x 10's 034998 PKR 345.16 PKR 17.26/tablet 🔒 Pharma Pro
Lopec Losartan 100 mg Tablet 1 x 10's 034999 PKR 345.16 PKR 34.52/tablet 🔒 Pharma Pro
Modopine Amlodipine 5 mg Tablet 2 x 10's 030723 PKR 201.92 PKR 10.10/tablet 🔒 Pharma Pro
Modopine Amlodipine 10 mg Tablet 2 x 10's 030724 PKR 322.72 PKR 16.14/tablet 🔒 Pharma Pro
Promy Omeprazole 20 mg Capsule 1x 14's 034997 PKR 248.51 PKR 17.75/capsule 🔒 Pharma Pro
Promy Omeprazole 20 mg Capsule 100's 034997 PKR 1,499.81 PKR 15.00/capsule 🔒 Pharma Pro
Rocoz Simvastatin 10 mg Tablet 1 x 10's 034988 PKR 286.48 PKR 28.65/tablet 🔒 Pharma Pro
A to Z

All 23 Citi pharma brands in Pakistan

  • *Askprin Acetylsalicylic acid (Aspirin) · 150 mg tablet, 75 mg tablet
  • Asknid Metronidazole · 200 mg tablet, 400 mg tablet
  • Askprol Paracetamol · 120 mg/5 mL suspension, 500 mg tablet
  • Avazin Cetirizine · 10 mg tablet
  • Cefask Cefixime · 100 mg/5 mL suspension, 200 mg capsule, 200 mg/5 mL suspension
  • Citi Chew Ascorbic acid · 500 mg tablet
  • Citiquin Hydroxychloroquine · 200 mg tablet
  • Clopeg Clopidogrel · 75 mg tablet
  • Duetec Ranitidine · 150 mg tablet, 300 mg tablet
  • Escitram Escitalopram · 10 mg tablet
  • Floxcip Ciprofloxacin · 250 mg tablet, 500 mg tablet
  • Flucogals Fluconazole · 150 mg capsule, 50 mg capsule
  • Flucogals Dry Fluconazole · 50 mg/5 mL suspension
  • Kalos Ibuprofen · 200 mg tablet, 400 mg tablet, 600 mg tablet
  • Lenon Levofloxacin · 250 mg tablet, 500 mg tablet
  • Lonirupol Allopurinol · 100 mg tablet, 300 mg tablet
  • Lopec Losartan · 100 mg tablet, 50 mg tablet
  • Modopine Amlodipine · 10 mg tablet, 5 mg tablet
  • Promy Omeprazole · 20 mg capsule
  • Rocoz Simvastatin · 10 mg tablet, 20 mg tablet, 40 mg tablet
  • Taximecit Cefotaxime · 1 g injection, 250 mg injection, 500 mg injection
  • Triaxonecit Ceftriaxone · 1 g injection, 2 g injection, 250 mg injection
  • Zyask Azithromycin · 250 mg capsule
Questions

Citi pharma: common questions

How many products does Citi pharma have in Pakistan?

Citi pharma ltd has 54 registered medicine presentations in Pakistan, sold under 23 brands and covering 22 generic medicines.

What are the main brands of Citi pharma?

By number of registered strengths and packs, its largest brands are Triaxonecit (Ceftriaxone), Cefask (Cefixime), Flucogals (Fluconazole), Askprol (Paracetamol) and Kalos (Ibuprofen). This is not a sales ranking.

Which therapy areas does Citi pharma cover?

The most products are in Anti-infectives (29), Pain & musculoskeletal (8), Cardiovascular (7), Gastrointestinal & hepatology (4) and Hematology & thrombosis (3).

Where can I see Citi pharma medicine prices?

Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.

MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Citi pharma ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved November 11, 2026, from https://medinfobase.com/company/citi-pharma-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.

Medicine brands A–Z:ABCDEFGHIJKLMNOPQRSTUVWXYZ0-9